BDPT BioAdaptives Inc

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety

Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes

LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield Laboratory Services, a trusted provider of sports supplement testing specializing in World Anti-Doping Agency (WADA) compliance.

TruShield™ is widely recognized in the athletic community for its rigorous, accredited testing protocols, trusted by professional sports organizations worldwide, including the Ultimate Fighting Championship® (UFC). At the UFC’s recommendation, BioAdaptives submitted MyndMed™ to TruShield™ for comprehensive analysis to verify purity and confirm the absence of any WADA-prohibited substances.

Following extensive testing, TruShield has confirmed that MyndMed™ contains no banned or prohibited ingredients and meets the highest safety standards for competitive athletes. This clearance ensures that UFC athletes can use MyndMed™ with complete confidence in its compliance with anti-doping regulations.

“Athlete safety is our top priority,” said James Keener, CEO of BioAdaptives. “We always strive to produce formulas that are not only effective but also meet the highest standards of quality and compliance. TruShield™’s verification confirms that MyndMed™ can be trusted by elite athletes competing under WADA regulations.”

This approval paves the way for MyndMed™ to be integrated into the UFC’s pool of approved nutritional supplements, allowing fighters to benefit from its focus, reaction time, and cognitive performance support without risk of violating anti-doping regulations.

MyndMed™’s formula, developed by BioAdaptives’ research team, incorporates a precise blend of botanical extracts, amino acids, and neuro-support nutrients designed to support neurotransmitter balance, mitochondrial energy production, and neural resilience under the high-stress demands of professional competition.

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based natural health and wellness products for both humans and animals. Its formulations leverage cutting-edge research in stem cell biology, adaptogens, and regenerative nutrition. The company’s mission is to enhance the quality of life through innovation that works in harmony with the body’s natural processes.

For more information, visit: .

Contact:

Emily Harrison

Investor Relations

BioAdaptives, Inc.

(702) 659-8829



EN
20/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAdaptives Inc

 PRESS RELEASE

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meetin...

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World ...

 PRESS RELEASE

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge ...

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and ...

 PRESS RELEASE

BioAdaptives Announces National Launch of Pawpa™ Regen

BioAdaptives Announces National Launch of Pawpa™ Regen Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation LAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of , a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nationwide at the end of July 2025. This breakthrough form...

 PRESS RELEASE

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for...

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- . (OTC: BDPT), through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, validated through rigorous clinical testing and the innovative APBAR® r...

 PRESS RELEASE

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Tr...

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone. During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was e...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch